| Methods |
Unclear if this is a randomised controlled trial. |
| Participants |
23 participants (age nm; sex nm) with newly diagnosed sarcoma (stage nm) treated with doxorubicin (cumulative dose nm, but ≥ 150 mg/m2; peak dose (i.e. maximal dose received in 1 week) nm; infusion duration in the control group 72 hours, infusion duration in the dexrazoxane group nm). No prior anthracycline therapy. Prior cardiac radiotherapy nm. Prior cardiac dysfunction yes (some participants had pretreatment elevation of high sensitivity troponin T, exact number nm). |
| Interventions |
Dexrazoxane (ratio of study drug to doxorubicin nm; timing of administration nm) (N = 10) versus no cardioprotective intervention (N = 13) |
| Outcomes |
Heart failure (different abnormalities on speckle tracking echocardiography); in the abstract no clear dichotomous results were provided. |
| Notes |
Unclear if this study is eligible for inclusion. Unclear if this is an ongoing or completed study. Length of follow‐up nm. Cumulative anthracycline dose per treatment group nm. Age per treatment group nm. |
